Related Experiment Video
Updated: Dec 22, 2025
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
[Delivery of Anticancer Drugs Using a Supramolecular Complex to Cancer Tissues Having High Interstitial Fluid
1Department of Physical Pharmaceutics, Graduate School of Phamaceutical Sciences, Kumamoto University.
Abstract:
Pancreatic cancer is the fourth-leading cause of death from cancer in Japan, after lung, colorectal, and stomach cancers and has the lowest survival among these tumors, because of not only no symptoms, no screening tool and no biomarkers but also high rates of recurrence and metastasis. In addition, pancreatic cancer has excessive stroma which serves as a severe biological barrier for anticancer drug delivery and successful treatment. Therefore, there are many challenges for drug delivery systems for the treatment of pancreatic cancer. Recently, we developed self-assembly PEGylation retaining activity (SPRA) technology, which comprises a reversible pegylated protein complex without loss of bioactivity. SPRA technology is based on a host-guest interaction between PEGylated β-cyclodextrin and adamantane-appended protein. In this review, first pancreatic cancer is introduced, second, principle drug delivery systems for the treatment of pancreatic cancer are described, and third the concept of SPRA technology as well as examples of SPRA proteins, especially focusing on the potential of SPRA-bromelain for treatment of pancreatic cancer, are introduced.
Insights
Pancreatic cancer presents significant treatment challenges due to its aggressive nature and drug delivery barriers. A novel self-assembly PEGylation retaining activity (SPRA) technology shows promise for improving drug delivery and pancreatic cancer treatment.
Area of Science:
- Oncology
- Biotechnology
- Drug Delivery Systems
Background:
- Pancreatic cancer is a leading cause of cancer death in Japan with poor survival rates.
- Challenges in pancreatic cancer treatment include lack of early symptoms, screening tools, biomarkers, and high recurrence rates.
- Excessive tumor stroma in pancreatic cancer acts as a biological barrier to drug delivery and treatment efficacy.
Purpose of the Study:
- To introduce pancreatic cancer and current drug delivery systems for its treatment.
- To present the novel self-assembly PEGylation retaining activity (SPRA) technology.
- To highlight the potential of SPRA technology, specifically SPRA-bromelain, for pancreatic cancer treatment.
Main Methods:
- Development of self-assembly PEGylation retaining activity (SPRA) technology.
- Utilizing host-guest interaction between PEGylated β-cyclodextrin and adamantane-appended protein.
- Reviewing existing drug delivery systems and introducing SPRA technology and its applications.
Main Results:
- SPRA technology enables reversible pegylated protein complex formation without loss of bioactivity.
- SPRA technology addresses challenges in drug delivery for pancreatic cancer.
- SPRA-bromelain demonstrates potential for pancreatic cancer treatment.
Conclusions:
- SPRA technology offers a promising approach for overcoming drug delivery barriers in pancreatic cancer.
- Further research into SPRA-bromelain could lead to improved therapeutic strategies for pancreatic cancer.
- The development of innovative drug delivery systems is crucial for enhancing pancreatic cancer treatment outcomes.
